CHEYNEY, Pa., April 4, 2024 /PRNewswire/ — Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting preclinical data on its next-generation anti-CD20 antibody, NAV-006, and ICAM-1 refractory antibody-drug…



Leave a Reply

Your email address will not be published. Required fields are marked *